Today: 15 June 2026
Browse Category

NASDAQ:ABVX 20 November 2025 - 2 June 2026

Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax shares plunged 33.7% to $86.01 after hours on Nasdaq despite its ulcerative colitis drug obefazimod hitting the main goal in a 44-week Phase 3 trial. Both 25 mg and 50 mg doses showed over 50% clinical remission versus 10.4% for placebo. No new safety signals reported. Abivax plans a U.S. FDA filing late Q4 2026. Cash reserves stood at €491.6 million at March-end, funding into Q4 2027.
2 June 2026
···
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (NASDAQ: ABVX) rose about 5.3% to $145.31 in premarket trading Friday, with U.S. markets the main venue as Euronext remained closed for St. Stephen’s Day. The stock has surged in December amid Eli Lilly takeover rumors, recent inclusion in the Nasdaq Biotechnology Index, and ongoing interest in its ulcerative colitis drug obefazimod.
26 December 2025
···
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

Abivax shares jumped about 10% to $126 in early U.S. premarket trading after reports of renewed takeover speculation involving Eli Lilly and confirmation of Abivax’s addition to the Nasdaq Biotechnology Index. French media said Lilly representatives met with France’s Treasury about a possible acquisition, though Reuters could not confirm the meeting. Both companies declined to comment on the rumors.
22 December 2025
····
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

Abivax shares fell about 5% in U.S. and Paris trading after reporting a nine-month net loss of €254.1 million, up from €136.9 million a year earlier. Cash and cash equivalents stood at €589.7 million as of September 30, expected to fund operations into Q4 2027. Investors weighed widening losses against a strong cash position and ongoing takeover speculation.
16 December 2025
···
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax shares surged as much as 20% on December 10, 2025, in Paris trading amid market rumors of a possible takeover bid by Eli Lilly. The stock hit a 52-week high near €126.60, with market value reaching about €9.7 billion. Abivax declined to comment, and no formal offer has been announced. U.S.-listed ADRs also jumped over 11% in pre-market trading.
10 December 2025
····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax shares surged 8% to $121.94 Thursday afternoon on heavy volume after fresh takeover rumors involving AstraZeneca. The French biotech’s stock is up about 1,450% year-to-date, fueled by strong Phase 3 ulcerative colitis data and M&A speculation. No deal has been confirmed by either company. Intraday volume reached 3.75 million ADSs, far above recent averages.
20 November 2025
··

Stock Market Today

  • Invesco S&P 500 Equal Weight Consumer Discretionary ETF (RSPD) Surges Above 200-Day Moving Average
    June 15, 2026, 4:24 PM EDT. Shares of Invesco's S&P 500 Equal Weight Consumer Discretionary ETF (RSPD) climbed above their critical 200-day moving average of $56.53 on Monday, reaching $57.37. This technical indicator, which investors use to identify long-term trends, signals potential bullish momentum as RSPD shares rose about 1% during the session. The ETF's price sits near the upper end of its 52-week range, between a low of $50.86 and a high of $60.34. Crossing the 200-day moving average often draws investor attention as a sign of strength in the stock's trajectory.

Latest articles

BitMine stock up as Ethereum treasury reaches 5.62M ETH ahead of BMNP debut

BitMine stock up as Ethereum treasury reaches 5.62M ETH ahead of BMNP debut

15 June 2026
BitMine Immersion Technologies shares jumped 6.7% to $17.19 as the company disclosed holding 5.62 million ETH—4.66% of all Ethereum—plus $502 million in cash and marketable securities, ahead of Tuesday’s NYSE debut of its 9.5% Series A preferred stock (BMNP), which is expected to pay weekly dividends.
S&P 500, Nasdaq Post Gains After Close; Oil Drops on U.S.-Iran Deal

S&P 500, Nasdaq Post Gains After Close; Oil Drops on U.S.-Iran Deal

15 June 2026
S&P 500 surged 1.77% and Nasdaq jumped 2.93% as falling oil prices and easing inflation fears drove a broad rally, with chip stocks like Micron up 10.8% and AMD up 6.9%, while energy shares tumbled over 3% after a preliminary U.S.-Iran framework raised hopes for reopening the Strait of Hormuz, directly impacting inflation, Fed rate expectations, and corporate costs.
Go toTop